Hepatitis C Patients with HIV Co-Infection Vulnerable to Serious Liver Disease Despite Antiretroviral Therapy

Published Online: Friday, May 23, 2014
Follow Pharmacy_Times:
A study finds that patients co-infected with hepatitis C and HIV who are receiving antiretroviral therapy are 80% more likely to have serious liver disease than those with hepatitis C alone.

Co-infection with HIV in addition to hepatitis C virus (HCV) carries a higher risk of serious liver disease in patients even when they are receiving antiretroviral therapy (ART) than that found in patients with HCV alone, according to a new study by researchers at the University of Pennsylvania.
 
The study, published in the March 18, 2014, issue of Annals of Internal Medicine, compared outcomes in patients co-infected with HIV and HCV who were undergoing ART treatment with patients who have chronic HCV alone. HCV co-infection occurs in 10% to 30% of HIV-infected patients, according to the study authors.
 
To read the rest of this article on SpecialtyPharmacyTimes.com, click here.

Related Articles
The FDA has granted priority review to Merck’s chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.
Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).
Many states implement unlawful and life-threatening restrictions on Medicaid coverage for the hepatitis C virus drug, sofosbuvir.
California’s Affordable Care Act health insurance exchange marketplace is the first in the nation to enact a payment cap policy for expensive specialty drugs.
Latest Issues
$auto_registration$